Thomas J. Herzog, MD

Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

January 15th 2025

Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.

Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance

January 8th 2025

Panelists discuss PARP inhibitor resistance in ovarian cancer and explore strategies to overcome this challenge, including findings from the PRESERVE-004 trial evaluating gotistobart plus pembrolizumab, along with other potential treatment options. Additionally, they review insights from the SOPRANO trial regarding the management of oligometastases or oligoprogression in ovarian cancer.

Overview of PRIMA - Niraparib 1L Maintenance

January 1st 2025

Panelists discuss the implications of PFS and OS data from the PRIMA trial evaluating niraparib as first-line maintenance therapy in advanced ovarian cancer, and the impact of these findings on the treatment paradigm, as well as new insights from the GEICO-88R study on long-term responders to niraparib. They also explore emerging maintenance strategies, including IO combination therapies and hormonal therapies, with a focus on ongoing trials such as rucaparib plus nivolumab, atezolizumab plus bevacizumab, and olaparib plus cediranib.

Optimizing PARP Inhibitor Duration

December 25th 2024

Panelists discuss how the duration of PARP inhibitor (PARPi) therapy typically differs between the first-line and second-line settings in advanced ovarian cancer treatment.

Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

December 18th 2024

Panelists discuss how frontline maintenance therapy options for advanced ovarian cancer are influenced by key factors, such as a patient’s HRD status, and when a combination approach with PARP inhibitors and bevacizumab might be preferred over monotherapy.

Role of Genomic Instability Scores in Treatment Selection

December 11th 2024

Panelists discuss how genomic instability scores, including HRD vs HRP profiles, influence treatment selection and sequencing in ovarian cancer, particularly in guiding the use of PARP inhibitors and other targeted therapies in the maintenance setting, and how these scores may prompt adjustments to standard treatment approaches.

Biomarker Testing in Advanced Ovarian Cancer

December 4th 2024

Panelists discuss how biomarker testing for advanced ovarian cancer, including when and which biomarkers to test (such as HRD), plays a crucial role in guiding treatment decisions and personalizing patient care.

PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse

April 25th 2024

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations

August 2nd 2023

Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.

Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

August 2nd 2023

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

Commercially Available 
HRD Tests for Ovarian Cancer

July 27th 2023

The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.

Other Causes of HRD: Chromosomal LOH, LST, and TAI

July 27th 2023

Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.

Defining HRD and its Role in Ovarian Cancer

July 20th 2023

Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).

Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann

July 20th 2023

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.

Systemic Management of Ovarian Cancer: Closing Thoughts

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

May 27th 2020